title: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
abstract: Aromatase inhibitors are a useful therapeutic option in the management of endocrine-dependent advanced breast cancer. A single-dose administration of exemestane (FCE 24304; 6-methylenandrosta-1,4-diene-3,17-dione), a new irreversible aromatase inhibitor, was investigated in 29 healthy postmenopausal female volunteers. The compound, given at p.o. doses of 0.5, 5, 12.5, 25, 50, 200, 400, and 800 mg (n = 3-4), was found to be a well tolerated, potent, long-lasting, and specific inhibitor of estrogen biosynthesis. The minimal dose which produced the maximum suppression of plasma estrogens was 25 mg, reducing plasma estrone, estradiol, and estrone sulfate to 35, 28, and 39% of basal values, respectively. This maximum suppression, observed at 3 days, persisted for at least 5 days after administration of a single dose. However, there was no interference on cortisol, aldosterone, 17-hydroxyprogesterone, or dehydroepiandrostenedione sulfate plasma levels. Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively. Plasma concentrations declined rapidly and fell under the detection limit (10 ng/ml) at 4 (50 mg) or 24 h (200 and 400 mg). No clinically significant adverse events which could be attributed to the drug were reported. Apart from transient eosinophilia in 3 patients, all biochemical and hematological laboratory parameters were within 1.25-fold of the normal ranges.
authors.affiliation: Department of Medical Oncology, St. George's Hospital Medical School, London, England.
authors.forename: T R
authors.initials: TR
authors.lastname: Evans
authors.forename: E
authors.initials: E
authors.lastname: Di Salle
authors.forename: G
authors.initials: G
authors.lastname: Ornati
authors.forename: M
authors.initials: M
authors.lastname: Lassus
authors.forename: M S
authors.initials: MS
authors.lastname: Benedetti
authors.forename: E
authors.initials: E
authors.lastname: Pianezzola
authors.forename: R C
authors.initials: RC
authors.lastname: Coombes
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000735:Androstenedione / Q000097:blood; D047072:Aromatase Inhibitors; D003687:Dehydroepiandrosterone / Q000097:blood; D004967:Estrogens / Q000097:blood / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000097:blood* / Q000652:urine; D008875:Middle Aged; D013739:Testosterone / Q000097:blood
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D004967:Estrogens; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C056516:exemestane